Massimiliano Tognolini

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 10

Top Venues

Pharmaceuticals (Basel, Switzerland)

International journal of molecular sciences

Journal of medicinal chemistry

Expert opinion on therapeutic targets

Universita degli Studi di Parma

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Universita degli Studi di Parma Jan 18 2005

Italy

Aggregate professor :: Pharmacy

Publications

Helison R P Carmo, Isabella Bonilha, Joaquim Barreto Oliveira, Massimiliano Tognolini, Ilaria Zanotti, Andrei Carvalho Sposito
High-Density Lipoproteins at the Interface between the NLRP3 Inflammasome and Myocardial Infarction. International journal of molecular sciences 25 (2) (2024)
Helison R P Carmo, Isabella Bonilha, Joaquim Barreto Oliveira, Massimiliano Tognolini, Ilaria Zanotti, Andrei Carvalho Sposito
High-Density Lipoproteins at the Interface between the NLRP3 Inflammasome and Myocardial Infarction. International journal of molecular sciences 25 (2) (2024)
Claudio Festuccia, Miriam Corrado, Alessandra Rossetti, Riccardo Castelli, Alessio Lodola, Giovanni Luca Gravina, Massimiliano Tognolini, Carmine Giorgio
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence. Pharmaceuticals (Basel, Switzerland) 16 (10) (2023)
Massimiliano Tognolini, Alessio Lodola, Carmine Giorgio
Drug discovery: in silico dry data can bypass biological wet data? British journal of pharmacology (2023)
Lorenzo Guidetti, Riccardo Castelli, Laura Scalvini, Francesca Ferlenghi, Miriam Corrado, Carmine Giorgio, Massimiliano Tognolini, Alessio Lodola
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids. Pharmaceuticals (Basel, Switzerland) 15 (2) (2022)
Francesca Ferlenghi, Carmine Giorgio, Matteo Incerti, Lorenzo Guidetti, Paola Chiodelli, Marco Rusnati, Massimiliano Tognolini, Federica Vacondio, Marco Mor, Alessio Lodola
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph-Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice. Pharmaceuticals (Basel, Switzerland) 15 (1) (2021)
Carmine Giorgio, Marika Allodi, Simone Palese, Andrea Grandi, Massimiliano Tognolini, Riccardo Castelli, Alessio Lodola, Lisa Flammini, Anna Maria Cantoni, Elisabetta Barocelli, Simona Bertoni
UniPR1331: Small Eph/Ephrin Antagonist Beneficial in Intestinal Inflammation by Interfering with Type-B Signaling. Pharmaceuticals (Basel, Switzerland) 14 (6) (2021)
Carmine Giorgio, Ilaria Zanotti, Alessio Lodola, Massimiliano Tognolini
Ephrin or not? Six tough questions on Eph targeting. Expert opinion on therapeutic targets 24 (5) (2020)
Miriam Corrado, Carmine Giorgio, Elisabetta Barocelli, Giuseppe Vittucci Marzetti, Anna Maria Cantoni, Rosanna Di Lecce, Matteo Incerti, Riccardo Castelli, Alessio Lodola, Massimiliano Tognolini
Evaluation of the Anti-Tumor Activity of Small Molecules Targeting Eph/Ephrins in APC min/J Mice. Pharmaceuticals (Basel, Switzerland) 13 (4) (2020)
Matteo Incerti, Simonetta Russo, Donatella Callegari, Daniele Pala, Carmine Giorgio, Ilaria Zanotti, Elisabetta Barocelli, Paola Vicini, Federica Vacondio, Silvia Rivara, Riccardo Castelli, Massimiliano Tognolini, Alessio Lodola
Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Protein-Protein Interaction Inhibitors Targeting the EphA2 Receptor. Journal of medicinal chemistry 60 (2) (2017)

Massimiliano Tognolini.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Massimiliano Tognolini